期刊
FUTURE ONCOLOGY
卷 16, 期 22, 页码 1585-1595出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0188
关键词
afatinib; NSCLC; osimertinib; sequential treatment
类别
资金
- Boehringer Ingelheim
- Merck Sharp Dohme
- AstraZeneca
- Novartis
- Pfizer
- Bristol-Myers Squibb
- Mirati
- Takeda
- AbbVie
- Eli-Lilly
- Guardant Health
- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
Aim:To assess time-to-treatment failure (TTF) in US patients withEGFRmutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study.Patients & methods:Patients hadEGFRT790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF.Results:In 129 patients at US centers, median TTF was 28.4 months (90% CI: 27.0-34.1). Median overall survival was 47.6 months (90% CI: 35.5-51.5).Conclusion:Sequential afatinib-osimertinib in this US-treated population was associated with long median TTF and represents an effective, evidence-based treatment option for US patients withEGFRmutation-positive NSCLC not presenting with active brain metastases orde novoT790M.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据